New MRI dye shows promise for spotting brain tumors

NCT ID NCT06057168

First seen Feb 01, 2026 · Last updated May 13, 2026 · Updated 14 times

Summary

This study tested a new contrast agent called Elucirem (gadopiclenol) for MRI scans of brain gliomas. It involved 138 adults with new or returning brain tumors. The goal was to see if Elucirem produced better quality images than the standard agent Dotarem. Results showed Elucirem performed well in creating clear brain blood flow maps.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Debreceni Egyetem

    Debrecen, Hungary

  • IRCCS C.Mondino, Istituto Neurologico Nazionale, Fondazione

    Pavia, Italy

  • Independent Public Teaching Hospital no 1 Department of Interventional Radiology and Diagnostic Imaging

    Lublin, Poland

  • Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá

    Budapest, Hungary

  • Ospedale Papa Giovanni XXIII

    Bergamo, Italy

  • Ospedale San Raffaele- Neuroradiologia

    Milan, Italy

  • Pecsi Tudomanyegyetem Klinikai Kozpont

    Pécs, Hungary

  • Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Semmelweis Egyetem - Neurologiai Klinika

    Budapest, Hungary

  • Szpital Specjalistyczny im.L.Rydygiera

    Krakow, Poland

  • Uniwersyteckie Centrum Kliniczne w Gdansku

    Gdansk, Poland

Conditions

Explore the condition pages connected to this study.